📊 NOTV Key Takeaways
Is Inotiv, Inc. (NOTV) a Good Investment?
Inotiv is in severe financial distress with operating losses of $35.6M and net losses of $60.8M despite modest 4.5% revenue growth. The company faces a critical liquidity crisis (current ratio 0.27x) with only $15.2M cash against $410.4M long-term debt, generating negative operating cash flow of -$6.5M. With negative interest coverage and unsustainable profitability metrics, the business is burning cash and cannot service debt from operations.
Fundamentals indicate persistent losses, negative free cash flow, and acute liquidity stress (0.30x current ratio) alongside negative interest coverage. Modest 4.5% revenue growth and improved EPS loss are insufficient against high leverage (3.72x D/E) and weak margins. Without swift, sustained cash generation or balance sheet repair, distress or dilutive actions are likely.
Why Buy Inotiv, Inc. Stock? NOTV Key Strengths
- Modest revenue growth of 4.5% YoY suggests some market demand
- Gross profit of $30.2M indicates core product/service has some profitability potential
- Asset base of $702.4M provides some collateral value if restructured
- Modest YoY revenue growth (+4.5%)
- Positive gross profit ($30.16M) that could support future margin recovery
- Shareholders' equity remains positive (assets exceed liabilities)
NOTV Stock Risks: Inotiv, Inc. Investment Risks
- Severe liquidity crisis: current ratio of 0.27x and only $15.2M cash with $625.3M liabilities
- Unsustainable debt: $410.4M long-term debt with 5.32x debt-to-equity ratio and negative interest coverage of -8.3x
- Fundamental business model failure: negative operating cash flow (-$6.5M), negative free cash flow (-$13.8M), and -25.5% net margin indicate operations cannot sustain the business
- Profitability deterioration: -14.9% operating margin and -78.9% ROE demonstrate value destruction
- Liquidity runway at risk: company burning cash despite revenue, increasing default risk
- Severe liquidity shortfall (current 0.30x, quick 0.22x)
- High leverage with negative interest coverage (-3.8x) increasing refinancing risk
- Continued operating and net losses with negative FCF (-8.8% margin)
Key Metrics to Watch
- Quarterly operating cash flow trend and path to positive operations
- Debt restructuring or refinancing activities given liquidity crisis
- Gross margin expansion and cost structure reduction to improve operating leverage
- Cash position monthly burn rate and liquidity runway estimate
- Operating cash flow
- Current ratio
Inotiv, Inc. (NOTV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NOTV Profit Margin, ROE & Profitability Analysis
NOTV vs Healthcare Sector: How Inotiv, Inc. Compares
How Inotiv, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inotiv, Inc. Stock Overvalued? NOTV Valuation Analysis 2026
Based on fundamental analysis, Inotiv, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inotiv, Inc. Balance Sheet: NOTV Debt, Cash & Liquidity
NOTV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inotiv, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.10 indicates the company is currently unprofitable.
NOTV Revenue Growth, EPS Growth & YoY Performance
NOTV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $117.7M | -$14.9M | $-0.44 |
| Q1 2026 | $119.9M | -$27.6M | $-0.83 |
| Q3 2025 | $105.8M | -$14.9M | $-0.51 |
| Q2 2025 | $119.0M | -$14.9M | $-0.44 |
| Q1 2025 | $119.9M | -$15.4M | $-0.60 |
| Q3 2024 | $105.8M | $1.8M | $0.07 |
| Q2 2024 | $119.0M | -$10.0M | $-0.39 |
| Q1 2024 | $122.8M | -$15.4M | $-0.60 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inotiv, Inc. Dividends, Buybacks & Capital Allocation
NOTV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inotiv, Inc. (CIK: 0000720154)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NOTV
What is the AI rating for NOTV?
Inotiv, Inc. (NOTV) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NOTV's key strengths?
Claude: Modest revenue growth of 4.5% YoY suggests some market demand. Gross profit of $30.2M indicates core product/service has some profitability potential. ChatGPT: Modest YoY revenue growth (+4.5%). Positive gross profit ($30.16M) that could support future margin recovery.
What are the risks of investing in NOTV?
Claude: Severe liquidity crisis: current ratio of 0.27x and only $15.2M cash with $625.3M liabilities. Unsustainable debt: $410.4M long-term debt with 5.32x debt-to-equity ratio and negative interest coverage of -8.3x. ChatGPT: Severe liquidity shortfall (current 0.30x, quick 0.22x). High leverage with negative interest coverage (-3.8x) increasing refinancing risk.
What is NOTV's revenue and growth?
Inotiv, Inc. reported revenue of $238.5M.
Does NOTV pay dividends?
Inotiv, Inc. does not currently pay dividends.
Where can I find NOTV SEC filings?
Official SEC filings for Inotiv, Inc. (CIK: 0000720154) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NOTV's EPS?
Inotiv, Inc. has a diluted EPS of $-1.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NOTV a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Inotiv, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NOTV stock overvalued or undervalued?
Valuation metrics for NOTV: ROE of -78.9% (sector avg: 15%), net margin of -25.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NOTV stock in 2026?
Our dual AI analysis gives Inotiv, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NOTV's free cash flow?
Inotiv, Inc.'s operating cash flow is $-6.5M, with capital expenditures of $7.3M. FCF margin is -5.8%.
How does NOTV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -25.5% (avg: 12%), ROE -78.9% (avg: 15%), current ratio 0.27 (avg: 2).
Is Inotiv, Inc. carrying too much debt?
NOTV has a debt-to-equity ratio of 5.32x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.